“An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib”

Type of Cancer
Leukemia

Sponsor
CTI BioPharma

Protocol Number
PAC203

To Learn More Call
201-510-0910